Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label ABBV-400 study in selected advanced solid tumors
jRCT2031230534Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of telisotuzumab adizutecan in hepatocellular carcinoma (HCC), pancreatic adenocarcinoma (PDAC), biliary cancer and 4 more (7 arms), sponsored by AbbVie Inc. Primary endpoint: Objective Response Rate. Started Dec 2023; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
hepatocellular carcinoma (HCC)pancreatic adenocarcinoma (PDAC)biliary cancerEsophageal Squamous Cell Carcinoma (ESCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2031230534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230534.